Gbcs.Pk
GBCS.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.
Business. GBCS.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
GBCS.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.
GBCS.PK exhibits a challenging capital structure, with a negative total equity of -$6,210,540 and a debt-to-equity ratio of -4.1, indicating a high reliance on debt financing. The company's liquidity position is further strained by a current ratio of 0.3, suggesting limited short-term liquidity to cover its liabilities. Despite a negative net income of -$1,015,750, the company reported positive operating cash flow of $1,882,030, which may provide some near-term liquidity support.
Profitability metrics reveal a mixed picture. The company's return on equity is 16.36%, which is unusually high given the negative equity, and may not be a reliable indicator of performance. However, the return on assets is -3.12%, indicating that the company is not generating positive returns on its asset base. These figures suggest that the company is struggling to convert its assets into profitable operations, which is a concern in the healthcare services and equipment industry.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the risk of revenue volatility and exposes the company to regional economic or regulatory changes. The absence of segment or geographic breakdown in the financial data limits the ability to assess the company's exposure to different markets.
Looking at the growth trajectory, the company's recent financial performance shows a decline in operating income, with a loss of $1,817,640. The capital expenditure of -$443,610 indicates a reduction in investment in long-term assets, which may affect future growth potential. The company's free cash flow is negative at -$23,440, suggesting that it is not generating sufficient cash to fund operations and growth without external financing.
The risk assessment highlights liquidity as a medium concern, with the company's net cash position being negative after accounting for total debt. The dilution risk is currently low, but the company's reliance on debt financing and negative equity could increase the likelihood of future dilution if additional capital is required. The company's financial structure and performance raise concerns about its ability to sustain operations and meet obligations without further financial restructuring.
Recent events and filings indicate that the company has not disclosed any significant new developments or strategic initiatives. The lack of recent events or transcripts suggests limited public communication about the company's future plans or performance. This absence of information may indicate a lack of transparency or a focus on internal operations rather than public relations.
- GBCS.PK has a negative equity position and a high debt-to-equity ratio, indicating a significant reliance on debt financing.
- The company's liquidity position is weak, with a current ratio of 0.3 and a negative net cash position after debt.
- Despite a high return on equity, the company's return on assets is negative, suggesting poor asset utilization.
- The company's revenue is not diversified across segments or geographies, increasing its exposure to regional and operational risks.
- The company's capital expenditure is negative, indicating a reduction in investment in long-term assets, which may affect future growth.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- GBCS.PK Market data — financials · 2026-05-28
- Selectis Health Inc Market data — analyst estimates · 2026-05-28
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Revenue (YoY) (2025-12-31 vs 2024-12-31): 4.9%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 57.5%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 1,130.1%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 48.7%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 203.2%Derived (calculated)
- Net margin (FY 2025-12-31): -2.5%Derived (calculated)
- Return on equity (FY 2025-12-31): 16.4%Derived (calculated)
- Return on assets (FY 2025-12-31): -3.1%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.30xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): -6.25xDerived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 42.7%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -0.2%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -29.9%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 58.1%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -2.6%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 57.5%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -14.8%Derived (calculated)
- Long-term debt (annual): USD 13.41MSEC XBRL filing
- Total assets (annual): USD 32.58MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
- Revenue (annual): USD 41.44MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- Operating cash flow (annual): USD 1.88MSEC XBRL filing
- Pre-tax income (annual): USD -1.01MSEC XBRL filing